1. Home
  2. NICM vs LUNG Comparison

NICM vs LUNG Comparison

Compare NICM & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nicola Mining Inc. American Depositary Shares

NICM

Nicola Mining Inc. American Depositary Shares

HOLD

Current Price

$5.06

Market Cap

100.4M

Sector

N/A

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$2.91

Market Cap

97.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NICM
LUNG
Founded
1980
1995
Country
Canada
United States
Employees
25
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.4M
97.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NICM
LUNG
Price
$5.06
$2.91
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $3.70
AVG Volume (30 Days)
4.6K
★ 1.2M
Earning Date
11-27-2026
10-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 7.64
EPS
★ N/A
N/A
Revenue
N/A
★ $90,497,000.00
Revenue This Year
$355.99
$0.33
Revenue Next Year
$161.43
$8.68
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$4.71
$1.13
52 Week High
$7.00
$3.25

Technical Indicators

Market Signals
Indicator
NICM
LUNG
Relative Strength Index (RSI) 45.84 63.79
Support Level $4.71 $1.26
Resistance Level $5.68 $3.25
Average True Range (ATR) 0.25 0.34
MACD 0.03 0.04
Stochastic Oscillator 20.59 75.34

Price Performance

Historical Comparison
NICM
LUNG

About NICM Nicola Mining Inc. American Depositary Shares

Nicola Mining Inc is a junior exploration and custom milling company that is engaged in the business of identification, acquisition, and exploration of mineral property interests, together with custom milling partnerships at its Merritt Mill. The company holds interests in various claims at the following properties: the Treasure Mountain Property, New Craigmont Property, and Dominion Creek Property. Its portfolio of producing assets and development projects is mainly composed of copper, gold, and silver properties spread across British Columbia, Canada.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: